These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 25788265

  • 21. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma.
    Dayton TL, Gocheva V, Miller KM, Israelsen WJ, Bhutkar A, Clish CB, Davidson SM, Luengo A, Bronson RT, Jacks T, Vander Heiden MG.
    Genes Dev; 2016 May 01; 30(9):1020-33. PubMed ID: 27125672
    [Abstract] [Full Text] [Related]

  • 22. MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer.
    Taniguchi K, Sugito N, Kumazaki M, Shinohara H, Yamada N, Nakagawa Y, Ito Y, Otsuki Y, Uno B, Uchiyama K, Akao Y.
    Cancer Lett; 2015 Jul 10; 363(1):17-27. PubMed ID: 25818238
    [Abstract] [Full Text] [Related]

  • 23. SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma.
    Tai WT, Hung MH, Chu PY, Chen YL, Chen LJ, Tsai MH, Chen MH, Shiau CW, Boo YP, Chen KF.
    Oncotarget; 2016 Apr 19; 7(16):22193-205. PubMed ID: 26959741
    [Abstract] [Full Text] [Related]

  • 24. Upregulation of liver kinase B1 predicts poor prognosis in hepatocellular carcinoma.
    Tan X, Liao Z, Liang H, Chen X, Zhang B, Chu L.
    Int J Oncol; 2018 Nov 19; 53(5):1913-1926. PubMed ID: 30226588
    [Abstract] [Full Text] [Related]

  • 25. Nuclear PKM2 expression, an independent risk factor for ER after curative resection of hepatocellular carcinoma.
    Fan F, Wu H, Liu Z, Hou X, Chen W, Wang A, Lu Y.
    Biomed Pharmacother; 2016 Dec 19; 84():1858-1864. PubMed ID: 27894667
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. MicroRNA-122 affects cell aggressiveness and apoptosis by targeting PKM2 in human hepatocellular carcinoma.
    Xu Q, Zhang M, Tu J, Pang L, Cai W, Liu X.
    Oncol Rep; 2015 Oct 19; 34(4):2054-64. PubMed ID: 26252254
    [Abstract] [Full Text] [Related]

  • 29. Clinicopathological and prognostic significance of PKM2 protein expression in cirrhotic hepatocellular carcinoma and non-cirrhotic hepatocellular carcinoma.
    Liu Y, Wu H, Mei Y, Ding X, Yang X, Li C, Deng M, Gong J.
    Sci Rep; 2017 Nov 10; 7(1):15294. PubMed ID: 29127353
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species.
    Yokoyama M, Tanuma N, Shibuya R, Shiroki T, Abue M, Yamamoto K, Miura K, Yamaguchi K, Sato I, Tamai K, Satoh K.
    Int J Oncol; 2018 Mar 10; 52(3):881-891. PubMed ID: 29393401
    [Abstract] [Full Text] [Related]

  • 32. Antitumor activity of SR splicing-factor 5 knockdown by downregulating pyruvate kinase M2 in non-small cell lung cancer cells.
    Yan J, Zhang D, Han Y, Wang Z, Ma C.
    J Cell Biochem; 2019 Oct 10; 120(10):17303-17311. PubMed ID: 31106485
    [Abstract] [Full Text] [Related]

  • 33. Overexpression of pyruvate kinase M2 associates with aggressive clinicopathological features and unfavorable prognosis in oral squamous cell carcinoma.
    Wang Y, Zhang X, Zhang Y, Zhu Y, Yuan C, Qi B, Zhang W, Wang D, Ding X, Wu H, Cheng J.
    Cancer Biol Ther; 2015 Oct 10; 16(6):839-45. PubMed ID: 25970228
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Pyruvate kinase M2 regulates apoptosis of intestinal epithelial cells in Crohn's disease.
    Tang Q, Ji Q, Xia W, Li L, Bai J, Ni R, Qin Y.
    Dig Dis Sci; 2015 Feb 10; 60(2):393-404. PubMed ID: 24817408
    [Abstract] [Full Text] [Related]

  • 36. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.
    Sureban SM, Madhoun MF, May R, Qu D, Ali N, Fazili J, Weygant N, Chandrakesan P, Ding K, Lightfoot SA, Houchen CW.
    Oncotarget; 2015 Nov 10; 6(35):37200-15. PubMed ID: 26468984
    [Abstract] [Full Text] [Related]

  • 37. Metabolic signature genes associated with susceptibility to pyruvate kinase, muscle type 2 gene ablation in cancer cells.
    Jung Y, Jang YJ, Kang MH, Park YS, Oh SJ, Lee DC, Xie Z, Yoo HS, Park KC, Yeom YI.
    Mol Cells; 2013 Apr 10; 35(4):335-41. PubMed ID: 23515579
    [Abstract] [Full Text] [Related]

  • 38. Pyruvate kinase M2 affects liver cancer cell behavior through up-regulation of HIF-1α and Bcl-xL in culture.
    Dong T, Yan Y, Chai H, Chen S, Xiong X, Sun D, Yu Y, Deng L, Cheng F.
    Biomed Pharmacother; 2015 Feb 10; 69():277-84. PubMed ID: 25661370
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.
    Shukla S, Rizvi F, Raisuddin S, Kakkar P.
    Free Radic Biol Med; 2014 Nov 10; 76():185-99. PubMed ID: 25128467
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.